While there are many exciting market segments, the market for cell and gene therapy CDMO services is one of the most fascinating. A decade ago, there were only a handful of market competitors. Today, there are more than a hundred companies specializing in manufacturing and clinical trial support for cell and gene therapies (CGT)—and demand for their services continues to rise. [Read more…]
Longevity Medical Institute® Opens Federally Licensed Stem Cell and Regenerative Medicine Biotechnology Laboratory in Los Cabos
LOS CABOS, BAJA CALIFORNIA SUR, Mexico, March 3, 2026 — Longevity Medical Institute® today announced the opening of its federally licensed Stem Cell and Regenerative Medicine Biotechnology Laboratory, further expanding what is now one of the most comprehensive regenerative and advanced diagnostic medical campuses in Los Cabos. [Read more…]
BioLife Solutions Signs Multi-Year Supply Agreement with Qkine Limited to Expand its Product Portfolio into the Rapidly Growing Cytokines Market
BOTHELL, Wash. and Cambridge, UK, February 12, 2026 —BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer and supplier of bioproduction tools and services for the cell and gene therapy (CGT) market, announces it has entered into a multi-year supply agreement with Qkine Limited under which BioLife will distribute certain cytokine and growth factor products manufactured by Qkine for use in cell and gene therapy manufacturing. [Read more…]
Nucleus Biologics Launches Krakatoa® K500: A Pod-Based, On-Demand Media and Buffer Manufacturing System Transforming Scale Bioproduction
-
Produces 35–500 liters of sterile media and buffers on demand at point-of-use, reducing cost, complexity, and lead times
-
Pod-based, closed single-use system with integrated analytics, QR-code-driven execution, and automated digital batch records to support GMP-compliant manufacturing
San Diego, CA — February 10, 2026 — Nucleus Biologics, a leading provider of custom cell culture solutions and manufacturing technologies for advanced therapies, today announced the launch of Krakatoa® K500, the first bioreactor-scale, pod-based media and buffer manufacturing system designed to deliver sterile solutions on demand and at point-of-use. The system enables the co-location of cell culture media and buffer manufacturing and bioproduction. [Read more…]
Eli Lilly Commits Up to $2.4B to Orna Therapeutics in Major Bet on In Vivo CAR-T
In news announced yesterday (February 9, 2026), Eli Lilly revealed plans to acquire Orna Therapeutics for up to $2.4 billion, a truly staggering price tag. The move marks a decisive step toward the next generation of cell therapy: programming immune cells directly inside the patient rather than manufacturing them outside the body.
Importantly, this transaction is not centered on a single pipeline candidate, but on securing a platform technology that could reshape how CAR-T and other immune-reset strategies are developed and delivered across autoimmune disease and beyond. [Read more…]
- « Previous Page
- 1
- …
- 8
- 9
- 10
- 11
- 12
- …
- 64
- Next Page »